| Online-Ressource |
Verfasst von: | Yang, Mingya [VerfasserIn]  |
| Wang, Lei [VerfasserIn]  |
| Neuber, Brigitte [VerfasserIn]  |
| Wang, Sanmei [VerfasserIn]  |
| Sauer, Tim [VerfasserIn]  |
| Schubert, Maria-Luisa [VerfasserIn]  |
| Hückelhoven-Krauss, Angela [VerfasserIn]  |
| Kleist, Christian [VerfasserIn]  |
| Eckstein, Volker [VerfasserIn]  |
| Sellner, Leopold [VerfasserIn]  |
| Müller-Tidow, Carsten [VerfasserIn]  |
| Dreger, Peter [VerfasserIn]  |
| Schmitt, Michael [VerfasserIn]  |
| Schmitt, Anita [VerfasserIn]  |
Titel: | Dual effects of cyclooxygenase inhibitors in combination with CD19.CAR-T cell immunotherapy |
Verf.angabe: | Mingya Yang, Lei Wang, Ming Ni, Brigitte Neuber, Sanmei Wang, Wenjie Gong, Tim Sauer, Maria-Luisa Schubert, Angela Hückelhoven-Krauss, Ruixiang Xia, Jian Ge, Christian Kleist, Volker Eckstein, Leopold Sellner, Carsten Müller-Tidow, Peter Dreger, Michael Schmitt and Anita Schmitt |
E-Jahr: | 2021 |
Jahr: | 26 May 2021 |
Umfang: | 13 S. |
Fussnoten: | Gesehen am 06.07.2021 |
Titel Quelle: | Enthalten in: Frontiers in immunology |
Ort Quelle: | Lausanne : Frontiers Media, 2010 |
Jahr Quelle: | 2021 |
Band/Heft Quelle: | 12(2021) vom: 26. Mai, Artikel-ID 670088 |
ISSN Quelle: | 1664-3224 |
Abstract: | CAR-T cells targeting CD19 came into clinical practice for the treatment of B cell lymphoma in 2018. However, patients being treated for B cell lymphoma often suffer from comorbidities such as chronic pain, cardiovascular diseases and arthritis. Thus, these patients frequently receive concomitant medications that include NSAIDs like COX inhibitors. Celecoxib, a selective COX-2 inhibitor, and aspirin, a non-selective COX-1 and COX-2 inhibitor, are being used as anti-inflammatory, analgesic and anti-pyretic drugs. In addition, several studies have also focused on the anti-neoplastic properties of COX-inhibitors. As the influence of COX-inhibitors on CD19.CAR-T cells is still unknown, we investigated the effect of celecoxib and aspirin on the quantity and quality of CD19.CAR-T cells at different concentrations with special regard to cytotoxicity, activation, cytokine release, proliferation and exhaustion. A significant effect on CAR-T cells could be observed for 0.1 mmol/L of celecoxib and for 4 mmol/L of aspirin. At these concentrations, we found that both COX-inhibitors could induce intrinsic apoptosis of CD19.CAR-T cells showing a significant reduction in the ratio of JC-10red to JC-10green CAR-T cells from 6.46 ± 7.03 to 1.76 ± 0.67 by celecoxib and to 4.41 ± 0.32 by aspirin, respectively. Additionally, the ratios of JC-10red to JC-10green Daudi cells were also decreased from 3.41 ± 0.30 to 0.77 ± 0.06 by celecoxib and to 1.26 ± 0.04 by aspirin, respectively. Although the cytokine release by CD19.CAR-T cells upon activation was not hampered by both COX-inhibitors, activation and proliferation of CAR-T cells were significantly inhibited via diminishing the NF-ĸB signaling pathway by a significant down-regulation (about 45%) of expression of CD27 on CD4+/CD8+ CAR-T cells, followed by a clear decrease of phosphorylated NF-ĸB p65 in both CD4+/CD8+ CAR-T cells by a factor of 1.8. Of note, COX-inhibitors hampered expansion and induced exhaustion of CAR-T cells in an antigen stress assay. Collectively, our findings indicate that the use of COX-inhibitors is a double-edged sword that not only induces apoptosis in tumor cells but also impairs the quantity and quality of CAR-T cells. Therefore, COX-inhibitors should be used with caution in patients with B cell lymphoma under CAR-T cell therapy. |
DOI: | doi:10.3389/fimmu.2021.670088 |
URL: | kostenfrei: Volltext ; Verlag: https://doi.org/10.3389/fimmu.2021.670088 |
| kostenfrei: Volltext: https://www.frontiersin.org/articles/10.3389/fimmu.2021.670088/full |
| DOI: https://doi.org/10.3389/fimmu.2021.670088 |
Datenträger: | Online-Ressource |
Sprache: | eng |
Sach-SW: | Acetylsalycilic acid |
| CD19.CAR-T cells |
| Celecoxib |
| inhibitors |
| NSAIDs |
| Persistence |
K10plus-PPN: | 1761975218 |
Verknüpfungen: | → Zeitschrift |
|
|
| |
Lokale URL UB: | Zum Volltext |
Dual effects of cyclooxygenase inhibitors in combination with CD19.CAR-T cell immunotherapy / Yang, Mingya [VerfasserIn]; 26 May 2021 (Online-Ressource)